Trial Profile
Safety and efficacy of Anti-PD-1 monoclonal antibody (Nivolumab and Pembrolizumab) followed by CD3-retronectin activated T cell therapy in pre-treated patients with metastatic renal cell carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Jun 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Retronectin-induced T-cell therapy
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 12 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology